Peroxiredoxin 3 regulates breast cancer progression via ERK-mediated MMP-1 expression

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Peroxiredoxin 3 (PRDX3) is a mitochondrial enzyme involved in oxidative stress management.
• PRDX3 upregulation is observed during cancer development and progression.
• Its specific role in breast cancer metastasis, particularly triple-negative breast cancer, requires further elucidation.

Purpose of the Study:

• To investigate the role of PRDX3 in breast cancer progression and metastasis.
• To identify the molecular mechanisms by which PRDX3 influences cancer cell invasion and migration.
• To explore the relationship between PRDX3, Matrix Metalloproteinase-1 (MMP-1), and ERK signaling in breast cancer.

Main Methods:

• Gene silencing using shRNA to reduce PRDX3 levels in triple-negative breast cancer cell lines.
• Overexpression of PRDX3 to assess its impact on cell invasion and migration.
• Immunohistochemical staining of breast cancer tissues to correlate PRDX3 and MMP-1 expression.
• Pathway reporter arrays and luciferase assays to analyze signaling pathway activation.

Main Results:

• PRDX3 gene silencing inhibited cell migration and invasion in triple-negative breast cancer cells.
• PRDX3 overexpression promoted cancer cell invasion and migration, correlating with MMP-1 upregulation.
• A positive correlation between PRDX3 and MMP-1 expression was found in breast cancer tissues.
• ERK signaling pathway activation was identified as the mechanism for PRDX3-mediated MMP-1 transcriptional activation.

Conclusions:

• PRDX3 promotes breast cancer cell migration and invasion, key steps in metastasis.
• PRDX3 facilitates cancer spread by upregulating MMP-1 expression via ERK signaling activation.
• Targeting ERK signaling presents a potential therapeutic strategy to inhibit metastasis in triple-negative breast cancer.